Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR   US00484M1062

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/22/2014 07/23/2014 07/24/2014 07/25/2014 07/28/2014 Date
29.75(c) 30.38(c) 29.56(c) 29.51(c) 29.24(c) Last
321 597 313 114 436 164 232 527 417 954 Volume
-0.44% +2.12% -2.70% -0.17% -0.91% Change
More quotes
Company
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system. The company's two main products are Ampyra and Zanaflex... 
Surperformance© rating of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More about the company
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 364 M
EBIT 2014 30,7 M
Net income 2014 16,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 403 M
EBIT 2015 48,4 M
Net income 2015 31,7 M
Debt 2015 -
Yield 2015 -
PER 2014 70,85
PER 2015 43,00
Capi. / Sales 2014 3,35x
Capi. / Sales 2015 3,02x
Capitalization 1 218 M
More Financials
Latest news on ACORDA THERAPEUTICS INC
1d ago ACORDA THERAPEUTICS : Assigned Patent
5d ago ACORDA THERAPEUTICS : to Host Conference Call to Discuss Second Quarter 2014 Fin..
07/18 ACORDA THERAPEUTICS : Actavis Files ANDA with FDA to Market Generic Version of A..
07/15 ACORDA THERAPEUTICS : Actavis Seeks FDA Approval to Market Dalfampridine Extende..
07/14 ACORDA THERAPEUTICS : Actavis Files ANDA with FDA to Market Generic Version of A..
07/09 ACORDA THERAPEUTICS : Other Events (form 8-K)
06/26 ACORDA THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
06/26 ACORDA THERAPEUTICS : Announces Notification of ANDA Filing for AMPYRA®
06/23 ACORDA THERAPEUTICS : Entry into a Material Definitive Agreement, Creation of a ..
06/18 ACORDA THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
06/18 ACORDA THERAPEUTICS : Announces Pricing of $300 Million of 1.75% Convertible Sen..
06/16 ACORDA THERAPEUTICS : Announces Public Offering of Convertible Senior Notes Due ..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
Acorda Therapeutics Inc : Income Statement Evolution
More Financials
EPS Revisions
Acorda Therapeutics Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF